key: cord-0731553-jurvl2yt
authors: Steiner, Sophie; Schwarz, Tatjana; Corman, Victor M.; Gebert, Laura; Kleinschmidt, Malte C.; Wald, Alexandra; Gläser, Sven; Kruse, Jan M.; Zickler, Daniel; Peric, Alexander; Meisel, Christian; Meyer, Tim; Staudacher, Olga L.; Wittke, Kirsten; Kedor, Claudia; Bauer, Sandra; Besher, Nabeel Al; Kalus, Ulrich; Pruß, Axel; Drosten, Christian; Volk, Hans-Dieter; Scheibenbogen, Carmen; Hanitsch, Leif G.
title: SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity
date: 2022-03-10
journal: Front Immunol
DOI: 10.3389/fimmu.2022.840126
sha: c707c1828fa69ccdcd1d24d47844f373691976d1
doc_id: 731553
cord_uid: jurvl2yt

Morbidity and mortality of COVID-19 is increased in patients with inborn errors of immunity (IEI). Age and comorbidities and also impaired type I interferon immunity were identified as relevant risk factors. In patients with primary antibody deficiency (PAD) and lack of specific humoral immune response to SARS-CoV-2, clinical disease outcome is very heterogeneous. Despite extensive clinical reports, underlying immunological mechanisms are poorly characterized and levels of T cellular and innate immunity in severe cases remain to be determined. In the present study, we report clinical and immunological findings of 5 PAD patients with severe and fatal COVID-19 and undetectable specific humoral immune response to SARS-CoV-2. Reactive T cells to SARS-CoV-2 spike (S) and nucleocapsid (NCAP) peptide pools were analyzed comparatively by flow cytometry in PAD patients, convalescents and naïve healthy individuals. All examined PAD patients developed a robust T cell response. The presence of polyfunctional cytokine producing activated CD4(+) T cells indicates a memory-like phenotype. An analysis of innate immune response revealed elevated CD169 (SIGLEC1) expression on monocytes, a surrogate marker for type I interferon response, and presence of type I interferon autoantibodies was excluded. SARS-CoV-2 RNA was detectable in peripheral blood in three severe COVID-19 patients with PAD. Viral clearance in blood was observed after treatment with COVID-19 convalescent plasma/monoclonal antibody administration. However, prolonged mucosal viral shedding was observed in all patients (median 67 days) with maximum duration of 127 days. PAD patients without specific humoral SARS-CoV-2 immunity may suffer from severe or fatal COVID-19 despite robust T cell and normal innate immune response. Intensified monitoring for long persistence of SARS-CoV-2 viral shedding and (prophylactic) convalescent plasma/specific IgG as beneficial treatment option in severe cases with RNAemia should be considered in seronegative PAD patients.

Morbidity and mortality of COVID-19 is increased in patients with inborn errors of immunity (IEI). Age and comorbidities and also impaired type I interferon immunity were identified as relevant risk factors. In patients with primary antibody deficiency (PAD) and lack of specific humoral immune response to SARS-CoV-2, clinical disease outcome is very heterogeneous. Despite extensive clinical reports, underlying immunological mechanisms are poorly characterized and levels of T cellular and innate immunity in severe cases remain to be determined. In the present study, we report clinical and immunological findings of 5 PAD patients with severe and fatal COVID-19 and undetectable specific humoral immune response to SARS-CoV-2. Reactive T cells to SARS-CoV-2 spike (S) and nucleocapsid (NCAP) peptide pools were analyzed comparatively by flow cytometry in PAD patients, convalescents and naïve healthy individuals. All examined PAD patients developed a robust T cell response. The presence of polyfunctional cytokine producing activated CD4 + T cells indicates a memory-like phenotype. An analysis of innate immune response revealed elevated CD169 (SIGLEC1) expression on monocytes, a surrogate marker for type I interferon response, and presence of type I interferon autoantibodies was excluded. SARS-CoV-2 RNA was detectable in peripheral blood in three severe COVID-19 patients with PAD. Viral clearance in blood was observed after treatment with COVID-19 convalescent plasma/monoclonal antibody administration. However, prolonged mucosal viral shedding was observed in all patients (median 67 days) with maximum duration of 127 days. PAD patients without specific humoral SARS-CoV-2 immunity may suffer from severe or fatal COVID-19 despite robust T cell and normal innate immune response. Intensified monitoring for long persistence of SARS-CoV-2 viral shedding and (prophylactic) convalescent plasma/ specific IgG as beneficial treatment option in severe cases with RNAemia should be considered in seronegative PAD patients.

Severity of COVID-19 is associated with increased age, male sex, and comorbidities, such as diabetes, arterial hypertension or pulmonary disease (1) . In patients with inborn errors of immunity (IEI), morbidity and mortality of COVID-19 is increased (2) (3) (4) (5) (6) (7) (8) (9) . However, IEI form a very heterogeneous group of patients (10) . With <700 COVID-19 cases in IEI patients reported worldwide (11), a higher risk for severe disease courses was confirmed to occur in older patients and in those with comorbidities (2) . Identified immunological host factors include type I interferon (IFN) autoantibodies or disruption of type I IFN signaling, affecting innate immune response to SARS-CoV-2 (12, 13) . These autoantibodies are found frequently in APS-1 (autoimmune polyendocrine syndrome) patients (14) , however general frequency of type I IFN autoantibodies in PAD patients are currently unknown and other immunological mechanisms underlying the predisposition to severe disease courses remain to be determined.

With regard to humoral immunity, early clinical data from XLA patients suggested that lack of SARS-CoV-2 humoral immunity may be sufficiently compensated by innate and T cell immunity in order to prevent severe COVID-19 (2, (15) (16) (17) (18) (19) (20) . On the other hand, patients with Good's syndrome, a thymoma-associated hypogammaglobulinemia with B and/or T cell deficiency and lack of specific humoral immune response, were reported to be at significantly increased risk for severe COVID-19 and a high case fatality rate (12) . Observations in immunocompetent patients with mild COVID-19 disease, where SARS-CoV-2-specific antibodies are undetectable in 10-15% (21), further highlighted the relevance of non-antibody mediated immunity and levels of specific T cellular immunity were found to be similar, regardless of the presence or absence of SARS-CoV-2 antibodies (22) .

Data on SARS-CoV-2-specific T cell immunity in patients with primary antibody deficiency (PAD) is still rare. (Cross) reactive T cells against other endemic human coronaviruses were found in CVID patients (23) , and a group of five mild COVID-19 cases in PAD patients, with largely preserved specific antibody response, was recently reported to generate a robust T cell response (24) . In addition, studies in PAD patients reported detectable specific T cell responses after COVID-19 vaccination (25) (26) (27) (28) .

Analyzing T cellular and innate immune response in severe COVID-19 in PAD patients without specific humoral immunity may help to identify necessary and redundant aspects of immune response to COVID-19 and is important to understand the different clinical outcomes in patients with antibody deficiency.

In the present study, we report clinical and immunological findings of 5 PAD patients with severe COVID-19 that failed to generate a specific humoral immune response to SARS-CoV-2. All patients presented with respiratory insufficiency due to COVID-19 pneumonia and two patients developed a fatal disease course. SARS-CoV-2 reactive T cells to spike (S) and nucleocapsid (NCAP) peptide pools were analysed comparatively by flow cytometry in PAD patients, convalescents, and naïve healthy individuals. We analyzed innate immune response by assessing CD169 (also termed: sialic acid-binding immunoglobulin-like lectin 1 or SIGLEC1) expression on monocytes. The activation of the type I IFN pathway results in a rapid increase of SIGLEC1 expression on the surface of macrophages and monocytes. Hence, type I IFN levels correlate with expression of SIGLEC1 on monocytes (29) . In addition, presence of type I IFN autoantibodies was examined. Clinical and virological outcomes after COVID-19 convalescent plasma (CP) and monoclonal antibody therapy in three PAD patients with RNAemia are presented.

Five patients with severe COVID-19 and confirmed diagnosis of CVID (n:3; fulfilling the European Society for Immunodeficiencies (ESID) criteria) and Good's syndrome (n:2), six mild COVID-19 convalescent healthy controls (CHC) and naïve healthy controls (HC) were included ( Table 1) . All cases were diagnosed by RT-PCR in nasopharyngeal swab. All patients, CHC and HC were not vaccinated against COVID-19. Blood samples from naïve HCs were drawn from the laboratory staff. Those naïve controls did not have a history of prior SARS-CoV-2 infection. Our study was approved by the Ethics Committee of CharitéUniversitätsmedizin Berlin in accordance with the 1964 Declaration of Helsinki and its later amendments (EA2/092/20 from June 4, 2020). All patients and controls gave written informed consent.

SARS-CoV-2 IgG against the S1 and N-terminal domain of SARS-CoV-2 spike was analyzed in serum by ELISA according to the manufacturer's instructions (Euroimmun Medizinische Labordiagnostika AG, Lübeck, Germany) and also by using fully automated Euroimmun Analyzer I (Euroimmun Medizinische Labordiagnostika AG, Lübeck, Germany). A positive IgG and IgA antibody response was determined by optical density (OD) ratios above 1.1. Titer of SARS-CoV-2 neutralizing IgG was assessed by the use of plaque reduction neutralization test (PRNT) as it has been previously described (30) .

RT-PCR testing for SARS-CoV-2 RNA in plasma or serum samples was done as previously described (31) and by using a preformulated oligonucleotide mixture (Tib-Molbiol, Berlin, Germany).

In all severe COVID-19 PAD patients, SIGLEC1 expression on monocytes was analyzed in EDTA whole blood based on a method described previously (32) . SIGLEC1 levels on monocytes were investigated using an admitted flow cytometry protocol at the clinical diagnostics laboratory (Labor Berlin GmbH). Samples were stained with mouse anti-human antibodies against SIGLEC1 (clone 7-239), CD14 and CD45 (antibodies purchased from Beckman Coulter).

Presence of anti-type I IFN autoantibodies was analyzed using an electrochemiluminescence immunoassay-platform (MSD, Rockville, U.S.) as described previously (33) . Light signal count (LSC) levels <1,980 for anti-Interferon-a antibodies and LSC levels <1,961 for anti-interferon-w antibodies are considered negative.

Plasma was collected from convalescent COVID-19 patients with confirmed neutralizing antibody titer in PRNT50 of at least 1:320 (21) and fulfilling all national standards for blood donation. Single-donor apheresis was conducted with Trima Accel System (Automated Blood Collection) Terumo BCT, Inc. Depending from body weight, two to three bags of 220 ml each were collected and frozen rapidly at <−30°C in less than 8 h after collection. Dosing of CP was conducted to achieve an expected PRNT50 of ≥1:40 in the recipient.

Time point of sampling for T cell analysis is indicated in Table 2 . Patients were off Dexamethasone treatment at least 10 days prior to sampling. Median time post symptom onset in healthy convalescent controls was 87 days (60-157 days). Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized whole blood using density gradient centrifugation and transferred to liquid nitrogen. PBMCs were thawed and rested for 24 h in IMDM medium supplemented with 10% fetal calf serum and 1% penicillin/ streptomycin. Cells were seeded with a concentration of 2 × 10 6 / ml. The background control was incubated with DMSO only and the positive control was stimulated with 3 µg/ml superantigen staphylococcal enterotoxin B (SEB). Stimulation for SARS-CoV-2 responsive T cells was performed using 1 µg/ml of peptide pools for S (two vials with N-term and C-term, PM-WCPV-S-1) and NCAP (PM-WCPV-NCAP-1) proteins (JPT Peptide Technologies GmbH, Berlin). Samples were incubated for 18 h under standard conditions (37°C, 5% CO 2 ). After 2 h of incubation with peptide pools, brefeldin A (BFA), a secretion inhibitor, was added to the cell culture.

PBMCs were stained on their surface with LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Thermo Fisher Scientific) following fixation and permeabilization (FoxP3 transcription factor staining buffer set, eBioscience). Staining for intracellular markers was conducted using human anti-CD3 BV650 (OKT3), -CD4 PerCp-Cy5.5 (SK3), -CD8 BV510 (RPA-T8), -CD137 PE (4B4-1), CD154 BV421 (24-31), IL-2 AP (MQ1-17H12), -IFNg BV605 (4S.B3), -TNFa AF700 (MAb11) (Biolegend). Samples were analyzed using CytoflexLX Flow Cytometer (Beckman Coulter) and FlowJo software (version 10.6.2, BD). A positive T cell response was defined as frequency of CD154 + CD137 + CD4 + T cells being ≥0.005% within total CD4 + T cells. Moreover, samples signals had to exceed the background signal by a minimum of 20%. This threshold value refers to the range in which 95% of all negative samples are. In order to exclude unspecific activation the background signal (DMSO sample) was subtracted from the peptide stimulated samples. Frequencies of effector cytokine producing antigen specific T cells were analyzed for IFNg, TNFa, IL-2 and seven different subsets were examined by Boolean combination gating strategy to identify single (sp), double (dp) or triple (tp) cytokine producing activated T cell populations.

Data analyses was performed using GraphPad Prism 6 software. Nonparametric statistical methods were used. Continuous variables were expressed as median and interquartile range (IQR). Univariate comparisons of T cell responses in two independent groups were performed using Mann-Whitney-U test. A p-value of <0.05 was considered statistically significant. Because of multiple testing p-values are considered descriptive.

PAD patients fulfilled ESID criteria for CVID (n:3) and Good's syndrome (n:2) (see Table 1 for detailed patient baseline characteristics). All five PAD patients had SARS-CoV-2 infections confirmed by RT-PCR in nasopharyngeal swab.

Severity was graded according to the Centre of Disease Control (34) . Extensive bilateral COVID-19 pneumonia was detected by chest CT in four cases (patient #1, #3, #4, #5), with onset of respiratory insufficiency occurring between days 8 and 20 PSO. Patient #2 had milder respiratory insufficiency (SpO2: 91% at room air) together with infiltrates in chest X-ray. Please refer to Table 2 and Supplementary Text 1 for detailed clinical case descriptions. All PAD patients (patient #1-5) failed to mount a specific antibody response to SARS-CoV-2 (negative for IgG and IgA antibodies) ( Table 2) . Serological response in RT-PCRconfirmed COVID-19 convalescent cohort showed positive SARS-CoV-2-IgG in three, borderline positive tests in two and a negative test result in one patient. SARS-CoV-2-IgA was positive in five individuals, while one convalescent individual was tested negative. As expected, SARS-CoV-2-IgG and -IgA was not detected in healthy controls (Supplementary Figure 1) .

For specific T cell responses we analyzed 4 PAD patients, 6 CHC and 6 naïve HC. For detailed gating strategy please refer to Supplementary Figure 2 .

All analyzed PAD patients had SARS-CoV-2 S reactive CD154 + CD137 + CD4 + T cells either to the N-(n:4) or C-terminal (n:3) part. 6/6 CHC had reactive CD4 + T cells to both SARS-CoV-2 S peptide pools, whereas naïve HCs had fewer N-(n = 4) and Cterminal (n = 2) responses. PAD patients showed significantly higher frequencies of CD4 + antigen specific T cells to the N-terminus compared to CHC (p = 0.005) and naïve HC (p = 0.014) ( Figure 1A) . CHC also showed significantly higher Spike Nterminal reactive CD4 + T cells compared to naïve HC (p = 0.02). Regarding C-terminal S reactive CD4 + T cells, PAD patients had higher frequencies compared to CHC (p = 0.02). Moreover, PBMC stimulation with SARS-CoV-2 NCAP peptide pool elucidated higher frequencies of antigen specific CD4 + T cells in 4/4 PAD patients compared to CHC (p = 0.03) and also in CHC compared to naïve HC (p = 0.04) ( Figure 1A) . Stimulation with the positive control SEB resulted in similar frequencies of CD4 + activated T cells among the investigated groups ( Figure 1B) . Patient #1 already expressed SARS-CoV-2-S-reactive T cells seven months prior to his severe COVID-19 disease as reported in our previous study on SARS-CoV-2 cross-reactive T cells in CVID patients (23) . Before SARS-CoV-2 infection patient #1 only expressed low levels of activated T cells (CD154 + CD137 + CD4 + ) reactive to N-terminus of SARS-CoV-2 S protein and also against S of human endemic corona viruses. During severe COVID-19 disease, activated CD4 + T cells reactive to SARS-CoV-2 C-terminal S and NCAP were also detectable and frequencies of activated, reactive T cells were generally much higher (1.8-2.2% CD154 + CD137 + CD4 + during COVID-19) (Supplementary Table 1) .

CD8 + T cell responses to peptide pools of SARS-CoV-2 structural proteins were observed in all 4 PAD patients. However, frequencies showed no differences compared to CHC and HC (Supplementary Figure 3A) . SEB stimulation serving as positive control resulted in comparable frequencies of activated CD137 + CD8 + T cells among the investigated groups (Supplementary Figure 3B ).

In all analyzed PAD patients and CHC we observed triple-positive (tp) antigen specific CD4 + T cells following stimulation with SARS-CoV-2 Spike (S) N-and C-terminal peptide pools (see Figure 2A and Supplementary Figure 2 for gating strategy and representative flow cytometry plots). PAD patients showed a higher expression of triple cytokine producing activated CD4 + T cells compared to CHC (C-terminal, p = 0.02) and naïve HC (N-terminal, p = 0.014) in response to SARS-CoV-2 S. Frequencies of S-and NCAP-reactive triple cytokine producing activated CD4 + T cells were significantly higher in CHC compared to HC (N-terminal, p = 0.03; C-terminal, p = 0.04) (Figure 2A) . CHC further expressed higher NCAP reactive triple cytokine producing activated CD4 + T cells compared to HC (p = 0.04). Overall highest responses to specific SARS-CoV-2 stimulation were observed for TNFa + IL-2 double cytokine producing activated CD4 + T cells with PAD patients showing significantly higher S N-terminal specific TNFa + IL-2 dp CD4 + T cells compared to CHC (p = 0.014) and HC (p = 0.005). This was as well observed for PAD patients compared to CHC (p = 0.03) after NCAP specific stimulation ( Figure 2B ). T cell responses for the remaining single and double cytokine producing CD4 + T cell subsets did not show a distinct pattern and are shown in Supplementary Figure 4 . Figures 5A-G) .

In three severe cases of COVID-19 (patient #1, #4 and #5), SARS-CoV-2-RNA was detected in peripheral blood with 3.2 × 10 4 , 7 × 10 4 and 8.8 × 10 4 copies/ml respectively ( Table 2) . Transfusion of 440 ml AB0-compatible COVID-19 CP with confirmed levels of neutralizing antibodies (PRNT50 ≥1:320) was conducted in patient #1 and #4 and was well tolerated. in peripheral blood was seen 6 days after treatment with monoclonal antibodies Casirivimab/Imdevimab and RT-PCR in plasma turned negative after 14 days. Serological follow-up showed detectable SARS-CoV-2-specific IgG (#1, #4, #5) and IgA (#1 and #4) respectively (see Table 3 ). Prolonged viral shedding (>40 days) was confirmed by RT-PCR in nasopharygeal swabs in all patients with patient #4 remaining positive for 127 days PSO ( Table 2 ).

SIGLEC1 on monocytes is a downstream molecule in IFN signaling serving as a surrogate marker of type I IFN signature (35) . Apart from patient #4, all patients had elevated levels of SIGLEC on monocytes, indicating a normal type I IFN response. Patient #4 expressed low levels of SIGLEC1 (1,423 molecules/ monocyte) despite RNAemia ( Table 2) . However, no autoantibodies against IFN-a or IFN-w were detected in any of our patients (Supplementary Table 2 ). Reanalysis of previously conducted whole exome sequencing of patient #1 revealed a heterozygous mutation in IFNAR1 (V307I), which was reported to be of no functional relevance [(12) and personal communication with JL Casanova and Q Zhang] . WES data of patient #3 did not reveal any suspect or disease causing mutations. In the remaining patients WES was not conducted.

In the present study of severe COVID-19 cases in PAD patients with undetectable SARS-CoV-2-specific antibodies, a robust T cell response was observed. Similar to convalescent immunocompetent patients, where polyfunctional SARS-CoV-2-specific T cells have been described (36) , triple cytokine-producing, activated T cells were observed in our PAD patients, indicating the generation of a memory-like phenotype (36, 37) . T cell response to COVID-19 was even stronger in PAD patients than in convalescent healthy controls (CHC), which is probably due to the generally milder disease course and slightly later median time point of sampling in the control group.

Innate immune response by type I IFN was shown to be of pivotal importance, and patients with defects in type I IFN signaling or autoantibodies against interferon-a or -w are at increased risk for severe COVID-19 (12, 13) . In IEI patients, type I IFN autoantibodies were reported for APS-1 patients (14) . Although described previously (38, 39) , impact of type I IFN autoantibodies on the high case fatality rate in Good's syndrome was never examined.

By assessing SIGLEC1 on monocytes, a robust ex vivo marker of type I IFN response, we observed an expected rise of expression levels in 4/5 patients. Low levels in patient #4 (Good's syndrome) and decline of SIGLEC1 expression levels in patient #1, despite RNAemia, prompted evaluation of anticytokine antibodies. However, we could not find anti-IFN-a or -IFN-w autoantibodies in any of our severe COVID-19 cases. Decreasing SIGLEC-1 expression during disease course might be related to concurrent medication with dexamethasone.

SARS-CoV-2 viral load, and in particular viral load in blood, was shown to be associated with increased risk of mortality (40, 41) . In the here reported severe COVID-19 patients without specific antibodies but detectable RNAemia, viral clearance in blood, and in part also clinical improvement, was clearly associated with administration of specific antibodies in convalescent plasma (CP) and monoclonal antibodies. COVID-19 CP has been used previously in IEI patients and its A B FIGURE 2 | Triple and double cytokine producing activated CD4 + T cell subsets in response to SARS-CoV-2 specific peptide stimulation. PBMCs of PAD (n = 4, red), CHC (n = 6, blue) and naïve HC (n = 6, grey) were stimulated with 1 µg/ml SARS-CoV-2 peptides or 3 µg/ml SEB. IFNg, TNFa and IL-2 tp activated CD4 + T cells were analyzed by Boolean combination gating strategy. Cytokine expression profile in tp activated CD4 + CD154 + CD137 + (A) T cells, and also TNFa + IL-2 dp (B) activated CD4 + T cells in response to SARS-CoV-2 peptide pools are shown. Median and interquartile range (IQR) are indicated. Statistical analysis was performed by non-parametric one-tailed Mann-Whitney-U test for comparison of control and patient groups. A p-value ≤0.05 was considered as statistically significant. p ≤0. 05 = *; p ≤0.001 = **. PAD patients are depicted by the following symbols: patient #1 *; patient #2 ▲; patient #3 ■; patient #4 ▼.

efficacy is usually evaluated clinically and according to viral load in nasopharyngeal or respiratory tract specimens (42) , but evaluation of virus neutralizing capacity in blood in IEI patients is missing (17, 43, 44) . It is unknown, whether a lack of specific humoral immunity to SARS-CoV-2 per se leads to an increased risk of RNAemia. Based on numerous mild COVID-19 cases in XLA patients (2, (15) (16) (17) (18) (19) (20) , at least generally persisting and high viral loads seem unlikely.

Data obtained during acute SARS-CoV-2 infection from larger cohorts of mild and severe COVID-19 cases in antibody deficient patients are needed to approach this question. Our data suggest a more differentiated approach to CP and SARS-CoV-2 monoclonal antibody treatment, which should include testing of viral load in blood and assessing antibody titer in the plasma recipient in order to detect accelerated reduction of transfused antibody levels related to virus neutralization and antibody consumption.

Despite a robust T cell response, we observed prolonged viral shedding > 40 days after initial positive RT-PCR in all our patients. Patient #4, suffering from Good's syndrome, even remained positive for 127 days. Prolonged viral shedding of SARS-CoV-2 in IEI patients was reported previously (2) . Although longer periods of persisting viral shedding are also reported in the general (45) and elderly seropositive population (46) , the extended duration of viral shedding in primary and secondary antibody deficiency suggests a role for antibodies in viral clearance. Of note, prolonged shedding was shown to be associated with marked within-host genomic evolution of SARS-CoV-2 with continuous turnover of dominant viral variants (47), warranting prolonged surveillance and testing of seronegative PID patients with COVID-19.

Overall, our observations of a robust T cellular immunity and detectable type I IFN innate response in severe COVID-19 patients without specific SARS-CoV-2 antibodies support the relevance of humoral immunity.

Our study included one CVID patient where SARS-CoV-2reactive T cells had been described prior to his COVID-19 disease (23). These preexisting cross-reactive T cells to SARS-CoV-2, were described in 35-90% of unexposed healthy individuals (36, 37, (48) (49) (50) (51) (52) , however their role during infection is a matter on ongoing debate. At least in our patient, preexisting reactive T cells in the absence of specific SARS-CoV-2 antibodies did not prevent severe COVID-19. However, the level of preexisting T cell immunity was rather low and increased substantially during infection. Therefore this observation does not allow to draw conclusions on possible protective levels of T cell immunity after vaccination.

As shown previously for XLA and CVID patients after vaccination against seasonal influenza or hepatitis B (53-55), induction of specific T cell immunity is also detectable after COVID-19 vaccination in IEI patients (25) (26) (27) (28) .

The increased levels of NCAP-reactive T cells suggest that patients unable of generating specific antibodies, might possibly benefit from vaccines immunizing against spike and nucelocapsid structures.

Having in mind the recent data on prophylactic monoclonal antibody treatment (56, 57) , our observations support the use of prophylactic antibody therapy in patients with known failure to mount a specific antibody response against SARS-CoV-2.

Although current data indicate, that commercially available immunoglobulin products already contain neutralizing SARS-CoV-2 antibodies to a certain extent (58) , neutralizing SARS-CoV-2 antibodies might not be detectable in commercially available products before Spring/Summer 2022 due to the long production process and safety regulations. Clinical effectiveness of SARS-CoV-2specific antibodies in immunoglobulin products against present and emerging SARS-CoV-2 variants remain to be investigated.

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

The studies involving human participants were reviewed and approved by the Ethics Committee of CharitéUniversitätsmedizin Berlin in accordance with the 1964 Declaration of Helsinki and its later amendments (EA2/092/20 from June 4, 2020). The patients/ participants provided their written informed consent to participate in this study. 

We acknowledge support from the German Research Foundation (DFG) and the Open Access Publication Fund of Charité-Universitätsmedizin Berlin.

We thank all patients and healthy controls who voluntary donated their blood for this study.

The and IFNg+ TNFa (E) dp activated CD4+ T cells in response to SARS-CoV-2 peptide pools are shown. Median and interquartile range (IQR) are indicated. Statistical analysis was performed by non-parametric one-tailed Mann-Whitney-U test for comparison of control and patient groups. A p-value ≤ 0.05 was considered as statistically significant. p ≤ 0.05 = *. PAD patients are depicted by the following symbols: patient #1 *; patient #2 ▲; patient #3 ■; patient #4 ▼.

Supplementary Figure 5 | Single, double and triple cytokine producing activated CD8+ T cells in response to SARS-CoV-2 specific peptide stimulation. IFNg, TNFa, or IL2 single (sp) or double (dp) or triple (tp) producing activated CD8+ T cells were analyzed by Boolean combination gating strategy. IFNg (A), TNFa (B) and IL2 (C) sp and IFNg+IL-2 (D), IFNg+TNFa (E) IL-2+TNFa (F) dp and IFNg+TNFa+IL2 tp activated CD8+ T cells in response to SARS-CoV-2 peptide pools are shown. Median and interquartile range (IQR) are indicated. Statistical analysis was performed by non-parametric one-tailed Mann-Whitney-U test for comparison of control and patient groups. A p-value ≤ 0.05 was considered as statistically significant. PAD patients are depicted by the following symbols: patient #1 *; patient #2 ▲; patient #3 ■; patient #4 ▼.

Supplementary Table 1 | Activated CD4+ T cell frequencies and cytokine response of patient #1 before and during SARS-CoV-2 infection. Please refer to Excel sheet Table 1 .

Supplementary 

Factors Associated With COVID-19-Related Death Using OpenSAFELY

Coronavirus Disease 2019 in Patients With Inborn Errors of Immunity: An International Study

Minor Clinical Impact of COVID-19 Pandemic on Patients With Primary Immunodeficiency in Israel

COVID-19 in the Context of Inborn Errors of Immunity: A Case Series of 31 Patients From Mexico

Outcome of SARS-CoV-2 Infection in 121 Patients With Inborn Errors of Immunity: A Cross-Sectional Study

COVID-19 in Patients With Primary and Secondary Immunodeficiency: The United Kingdom Experience

COVID-19 Infection in 10 Common Variable Immunodeficiency Patients in New York City

Clinical Outcome, Incidence, and SARS-CoV-2 Infection-Fatality Rates in Italian Patients With Inborn Errors of Immunity

Adverse COVID-19 Outcomes in Immune Deficiencies: Inequality Exists Between Subclasses

Human Inborn Errors of Immunity: 2019 Update on the Classification From the International Union of Immunological Societies Expert Committee

Coronavirus Disease 2019 in Patients With Inborn Errors of Immunity: Lessons Learned

Autoantibodies Against Type I IFNs in Patients With Life-Threatening COVID-19

Inborn Errors of Type I IFN Immunity in Patients With Life-Threatening COVID-19

Preexisting Autoantibodies to Type I IFNs Underlie Critical COVID-19 Pneumonia in Patients With APS-1

A Possible Role for B Cells in COVID-19? Lesson From Patients With Agammaglobulinemia

Two X-Linked Agammaglobulinemia Patients Develop Pneumonia as COVID-19

Treatment of COVID-19 With Remdesivir in the Absence of Humoral Immunity: A Case Report

The Clinical Course of COVID-19 Pneumonia in a 19-Year-Old Man on Intravenous Immunoglobulin Replacement Therapy for X-Linked Agammaglobulinemia

Possible COVID-19 Reinfection in a Patient With X-Linked Agammaglobulinaemia

Treatment of SARS-CoV-2 Relapse With Remdesivir and Neutralizing Antibodies Cocktail in a Patient With X-Linked Agammaglobulinemia

Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses

Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2

HCoV-and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients

Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients With Antibody Deficiency

Immunogenicity of Pfizer-BioNTech COVID-19 Vaccine in Patients With Inborn Errors of Immunity

Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies

SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does Their Best

Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency

Role of the Interferons in CD64 and CD169 Expressions in Whole Blood: Relevance in the Balance Between Viral-or Bacterial-Oriented Immune Responses

Virological Assessment of Hospitalized Patients With COVID-2019

Detection of 2019 Novel Coronavirus (2019-Ncov) by Real-Time RT-PCR

SIGLEC1 (CD169) as a Potential Diagnostical Screening Marker for Monogenic Interferonopathies

Mild COVID-19 Despite Autoantibodies Against Type I IFNs in Autoimmune Polyendocrine Syndrome Type 1

COVID-19) Treatment Guidelines. National Institutes of Health

CD169/SIGLEC1 Is Expressed on Circulating Monocytes in COVID-19 and Expression Levels Are Associated With Disease Severity

Robust T Cell Immunity in Convalescent Individuals With Asymptomatic or Mild COVID-19

Phenotype and Kinetics of SARS-CoV-2-Specific T Cells

Massiliense Infection in a Good's Syndrome Patient Negative for Human Immunodeficiency Virus and Anti-Interferon-g Autoantibody: A Case Report

Anti-Cytokine Autoantibodies in Autoimmunity: Preponderance of Neutralizing Autoantibodies Against Interferon-Alpha, Interferon-Omega and Interleukin-12 in Patients With Thymoma and/or Myasthenia Gravis

SARS-CoV-2 Viral Load Is Associated With Increased Disease Severity and Mortality

SARS-CoV-2 RNAemia and Proteomic Trajectories Inform Prognostication in COVID-19 Patients Admitted to Intensive Care

Use of Convalescent Plasma in COVID-19 Patients With Immunosuppression

Three Patients With X-Linked Agammaglobulinemia Hospitalized for COVID-19 Improved With Convalescent Plasma

Report: Convalescent Plasma, a Targeted Therapy for Patients With CVID and Severe COVID-19

Prolonged Shedding of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With COVID-19

Prolonged Viral Clearance of Severe Acute Respiratory Syndrome Coronavirus 2 in the Older Aged Population

Case Study: Prolonged Infectious SARS-CoV-2 Shedding From an Asymptomatic Immunocompromised Individual With Cancer

SARS-CoV-2-Reactive T Cells in Healthy Donors and Patients With COVID-19

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans With COVID-19 Disease and Unexposed Individuals

SARS-CoV-2-Specific T Cell Immunity in Cases of COVID-19 and SARS, and Uninfected Controls

Selective and Cross-Reactive SARS-CoV-2 T Cell Epitopes in Unexposed Humans

SARS-CoV-2-Derived Peptides Define Heterologous and COVID-19-Induced T Cell Recognition

Long-Lasting Memory-Resting and Memory-Effector CD4+ T Cells in Human X-Linked Agammaglobulinemia

Cellular and Humoral Influenza-Specific Immune Response Upon Vaccination in Patients With Common Variable Immunodeficiency and Unclassified Antibody Deficiency

T Cell Activity and Cytokine Production in X-Linked Agammaglobulinemia: Implications for Vaccination Strategies

REGEN-COV Antibody Combination and Outcomes in Outpatients With Covid-19

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

Rapidly Increasing SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic

Conflict of Interest: VC is named together with Euroimmun on a patent application filed recently regarding detection of antibodies against SARS-CoV-2. Authors CM, TM and OS are employed by Labor Berlin GmbH.The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.